Ocular hypotensive effects of medifoxamine.

Abstract

Medifoxamine is a novel monoamine re‐uptake inhibiting antidepressive drug which preferentially inhibits dopamine reuptake. In human volunteer studies it has been found to reduce significantly intraocular pressure after single oral doses of 300‐1000 mg, and to produce a small but statistically significant miosis. Its maximal ocular hypotensive action was less than that of oral timolol 20 mg. 1992 The British Pharmacological Society